The COVID-19 pandemic has driven advancements in vaccination technology, but there’s an urgent need for mucosal immune response-inducing and non-invasive, single-dose vaccines.
Most current vaccines for respiratory diseases rely on intramuscular injections, primarily activating a humoral immune response dependent on blood antibodies to neutralize the virus. Moreover, the liquid form of vaccines requires stringent low-temperature storage and a two- or three-dose schedule.
Innovative strategies required for enhancing respiratory disease vaccine efficacy!
In a remarkable breakthrough, researchers at the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have introduced an innovative “nano-micro composite” vaccine delivery concept.
Their groundbreaking approach involves a single-dose, dry powder, inhalable vaccine utilizing nano-micro composite multilevel structures. Successfully formulated in the laboratory, this vaccine has demonstrated efficacy in thwarting respiratory viral infection and transmission in animal models.
This approach holds promise against future infectious diseases and epidemics.
This innovative platform combines biodegradable microspheres with protein nanoparticles, presenting multiple antigens on their surface for a broad-spectrum immune response. Its nano-micro composite structure efficiently delivers antigens to the lungs, enhancing uptake by antigen-presenting cells. A single inhalation induces sustained release, fostering long-lasting humoral, cellular, and mucosal immunity.
The dry powder vaccine reduces storage costs, which is particularly beneficial in areas with limited refrigeration. The platform’s flexibility allows for the rapid development of various respiratory virus vaccines, marking a significant advancement in vaccination technology.
